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ABSTRACT 
 
Objective: To determine the prevalence of REM behavior disorder in the 
synucleinopathy patient population, treatments used, and effectiveness of these 
treatments.   
Background: Rapid eye movement (REM) sleep behavior disorder (RBD) is a 
sleep disorder characterized by loss of muscle atonia during the REM sleep 
stage, often manifesting in shouting, flailing, and kicking behaviors. These 
behaviors are generally associated with the content of the dream and patients 
report these dreams as unusually vivid. We have evaluated patients with 
Synucleinopathies (Multiple Systems Atrophy, Parkinson’s disease, and 
Dementia with Lewy Bodies) to examine the prevalence of RBD in this population 
and the presence of screening practices. In addition to the typical motor 
symptoms of these diseases, RBD, as a non-motor symptom, is a common 
precursor to these disorders.  
Methods: This study was conducted via a retrospective chart review and analysis 
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of 278 patients in the movement disorders clinic at Boston Medical Center from 
2011.  
Results: These patients had an average age of 71.6 years (± 8.4 years). Of these 
patients, 36.8% of those with Parkinson’s Disease, 66.6% of those with Multiple 
system atrophy, 61% of those with Lewy Body Dementia and 17.9% of those with 
Parkinsonism were comorbid for RBD. Of all charts reviewed 73.7% of the 
patients were screened for RBD and 46.8% of those with this disorder were 
undergoing treatment for it, 37.8% were taking melatonin(average 3.5mg 
±1.1mg) with a 57.1% improvement, while 62% were on Clonazepam(average 
.5mg ±.16mg) with a 56.5% improvement. 32.9% of our RBD population was 
found to be on SSRIs. 72.2% of our RBD population was male. 
Conclusion: It is evident that RBD has a high prevalence in this population and 
may be able to serve as a pre-clinical risk factor and diagnostic measure. Further 
study of the correlation between RBD and Synucleinopathies may allow for 
earlier and more accurate diagnosis, thereby having implications in the treatment 
of these neurodegenerative disorders. 
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INTRODUCTION 
 
Parasomnias 
 
  Parasomnias are one of the major subdivisions of sleep disorders; this 
subset is characterized as defective behaviors taking place during sleep and/or 
the passage into or out of sleep. Within the class of parasomnias, there are 3 
further subsets of disorders; categorized as disorders of arousal, disorders of 
rapid eye movement (REM) sleep or ‘other’. Disorders of arousal arise when 
elements of wakefulness present in non-REM sleep; these include sleep terrors, 
confusional arousals, and sleepwalking. Disorders of REM sleep involve ailments 
of the REM stage of sleep, this area includes REM sleep behavior disorder 
(RBD) and nightmares. The most frequently encountered parasomnias in a 
clinical setting are sleepwalking, sleep terrors, confusional arousals, and REM 
sleep behavior disorder (Matwiyoff & Lee-Chiong, 2010). 
 
REM sleep behavior disorder criteria and presentation 
 
  REM Sleep Behavior Disorder is a parasomnia affecting the REM stage of 
sleep, this disorder is marked by recurrent dream reenactment behaviors with 
superfluous motor activity resulting from a loss of typical muscle atonia 
(Claassen et al., 2010). A clinical feature of RBD is the presence of abnormal 
 2 
vocalizations. These utterances are loud and suggest unpleasant dream content 
often manifested in shouting and screaming. Abnormal motor behavior is also 
noted; these motor behaviors are dramatic and appear to be purposeful activities 
while the patient is asleep. Additionally, RBD patients have altered dream 
mentation in which the patient is most often defending themselves in these 
unusually vivid dreams. It has also been noted that RBD patients do not forget 
the dream content rapidly upon waking, as non RBD patients would. Instead it is 
frequently noted that those with RBD recall the vividness and details of these 
dreams for days to years (Bradley F Boeve, 2010). Recent studies indicate 89% 
of the recalled dreams of RBD patients involve the patient facing aggression 
(Olson, Boeve, & Silber, 2000). This is a large contrast to a study conducted on 
1,320 non-RBD dreams finding that only 34% involved malicious acts against the 
dreamer (Hall, 1951). 
 
  The International Classification of Sleep Disorders (ICSD)-2  produced by 
the American Academy of Sleep Medicine (AASM) requires the following for 
diagnosis of RBD (“International Classification of Sleep Disorders (ICSD-2) - 
American Academy of Sleep Medicine (AASM),” n.d.): 
  1) Existence of REM sleep without atonia, given by elevated  
  electromyography (EMG) tone or extreme burst-like(phasic) muscle tone  
  in the limb EMG readings of polysomnography (PSG) testing. 
  2) At least 1 of the following: 
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   a) Sleep related injury, or risk of sleep related injury associated  
   behaviors via history. 
    b) Atypical REM sleep activity as documented on PSG testing. 
  3) Lack of epilepsy resembling behavior during REM sleep, unless RBD  
  can be obviously isolated from any coexisting sleep-related seizure  
  disorder. 
  4) These sleep disturbances cannot be better attributed to another  
  disorder, medication use, or substance use.  
 
RBD epidemiology and history 
 
  In humans, REM sleep becomes evident between the 27th and 30th week 
of gestation. During childhood REM sleep achieves a stable pattern that persists 
through adulthood (Schenck, Bundlie, Ettinger, & Mahowald, 1986). Each sleep 
cycle lasts approximately 90 minutes, each of these cycles containing between 
20-30 minutes of REM sleep; thereby in a given night there will be 4 or 5 periods 
of REM sleep. Most slow wave sleep occurs during the first half of the night. 
During the second half of the night there is an increasing amount of stage two of 
sleep and bouts of REM sleep (Carlson & Carlson, 2011). As a result of REM 
sleep occurring more frequently later in the sleep cycle, so too are RBD 
symptoms and presentation seen during this time. 
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  REM sleep behavior disorder was first detailed in cat models in the 
1960’s. However, Most of our initial knowledge on RBD comes from a study 
conducted by Schenck and colleagues on 5 elderly RBD patients in 1986; this 
was the first research outlining RBD in a human model (Aurora et al., 2010). All 5 
of these subjects underwent PSG and neurological testing. Clinical histories were 
also taken, during which 2 out of the 5 patients reported the RBD episodes never 
occurring within 1 hour of falling asleep.  Patients were videotaped while sleeping 
as a part of the PSG. Motions such as hand movements, reaching and searching 
behaviors as well as punches and kicks were observed in all participants and 
were found to be congruent with dream recall in all 5 participants.  After analysis 
of the PSG data, Schenck et al. found all of the patients to exhibit phasic and 
desynchronized EEG waves during all REM periods recorded (Schenck et al., 
1986). These are abnormal patterns, atypical of typical REM sleep in healthy 
subjects.  
  
  Four of Schenck’s five participants were male, mirroring the predominance 
that is found towards males in the RBD population (Schenck et al., 1986).  The 
overall prevalence of RBD in the general population is reported to be 0.5% 
(Matwiyoff & Lee-Chiong, 2010). Recent research by Olson et al. has found 87% 
of RBD suffers are male, emphasizing the gender bias often reported in this 
condition. In the same study it was noted that out of 93 cases 32% had injured 
themselves during their RBD bouts, while 64% had assaulted their bed partners 
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(Olson et al., 2000). This is a great concern in the treatment and management of 
RBD patients as well as in ensuring their quality of life as many RBD patients find 
themselves unable able to share sleeping quarters with their partners.  
 
   Most frequently, RBD presents between ages 40 and 70. Rarely, RBD 
may develop in the teens or late 20’s, however, this is more typically associated 
with narcolepsy (Bradley F Boeve, 2010). The tendency for RBD to arise late in 
life varies from the other non-REM disorders of arousal; many of the other 
parasomnias present much earlier. Additionally, RBD effects a much greater 
portion of men whereas non-REM disorders are found equally in both sexes 
(Matwiyoff & Lee-Chiong, 2010). This gender disparity however is much less 
pronounced in cases of early-onset RBD; here men account for only 55-59% of 
suffers. RBD is considered to be early onset when it presents before age 50 (Ju, 
2013). 
 
 Polysomnography and REM sleep behavior disorder 
   
  While not always feasible, polysomnography testing is critical in the 
diagnosis of RBD and is part of the required criteria for ICSD-2 diagnosis 
(Bradley F Boeve, 2010). When used for the detection of RBD, PSGs involve 
numerous EMG recordings including leads to all limbs and the chin. These EMG 
recordings are utilized to detect atypical muscle activity. Electroencephalogram 
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(EEG) recordings are taken to monitor brain waves as a means to determine 
sleep stages and abnormalities in these stages and the transitions between 
them. Participants’ body temperatures are also noted as these will rise as the 
patient enters REM sleep. Additionally, PSG often records video during the night 
so night time behaviors may be observed and compared temporally with PSG 
data (Kunz & Mahlberg, 2010). REM sleep stage is defined via PSG by low 
amplitude mixed frequency EEG background, rapid eye movements, and low 
chin EMG tone. REM sleep without atonia (RWA) may be determined when there 
is continuous muscle activity in REM sleep with 50% of the REM period showing 
increased EMG activity in the chin. RWA is also characterized by abundant and 
brief muscle activity. To be considered RWA, this transient muscle activity must 
present 5 or more times in an epoch, each of these epochs must extend at least 
0.5 seconds (Bradley F Boeve, 2010). While the loss of atonia is required for 
RBD diagnosis, it alone is not sufficient to produce RBD behavior (Schenck et al., 
1986). 
 
  During RBD episodes patients may show muscle activity that is either 
tonic (sustained activity lasting 20-30 seconds) or phasic (burst-like lasting 
between 2-3 seconds) on EMG recordings (Verhave et al., 2011). Variations in 
limb activity have been observed between men and women. Studies have 
observed women to have more arm movements whereas men tend to exhibit 
more leg movement. This underscores the important of EMG placement on all 
 7 
limbs (Trotti, 2010). 
 
 
 
 
 
 
Figure 1. PSG recording of control and RBD case. Two thirty second period 
polysomnograms showing normal REM sleep (A) and REM sleep without atonia 
(B), a feature of RBD. In A, note the absence of EMG activity beside the three 
arrows, depicting the activity found in the Chin, upper, and lower limbs. The same 
muscle groups are noted in B by arrows, here abundant muscle tone is noted as 
evidence of the loss of muscle atonia. Figure annotated from Bradley F. Boeve 
2010.  
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Pathophysiology of RBD 
 
  While the neurological pathways responsible for REM sleep and RBD are 
not well understood, there are many hypotheses regarding the nuclei involved. 
Few post-mortem pathology studies have been conducted on human RBD 
patients with no other known neurological disorders. The two best currently 
understood animal models for RBD pathology are the cat and the rat (B F Boeve, 
Dickson, et al., 2007).   
 
  Research on the cat model of RBD pathology advocates for two motor 
systems being involved in typical REM sleep; one of which ensures muscle 
atonia while the other suppresses locomotor activity.  In this paradigm, the 
absence of motor activity typically found in normal REM sleep is due to inhibition 
of spinal motor neurons and a reduction in the drive of generating nuclei. The 
brain areas most studied for their effects on RBD in the cat model are the 
magnocellular reticular formation (MCRF), locus coeruleus, pedunculopontine 
nucleus (PPN), laterodorsal tegmental nucleus (LDTN), and the substantia nigra 
(SN).  The MCRF functions to hyperpolarize, and thereby inhibit, anterior horn 
cells in the spinal column through projections of the ventrolateral reticulospinal 
tract (VLST). Lesions experimentally produced in the MCRF release the tonic 
inhibition on these spinal motor neurons, leading to RWA behaviors. Similarly, 
lesions to the locus coeruleus, a nuclei located in the pons, results in RWA. 
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Interestingly, the size and extent of lesions in this area determines if complex 
behaviors are elicited during the RWA episodes (B F Boeve, Silber, et al., 2007). 
 
 
 
 
 
Figure 2. Proposed REM sleep modulation in the cat model. Each oval 
represents a distinct nuclei. Excitatory synapses are represented by plus 
signs, inhibitory synapses are noted by minus signs; the size of each of these 
symbols denotes the relative intensity of each synapse. This figure shows the 
proposed REM sleep pathways described in the text. Figure annotated from 
B.F. Boeve Silber et al. 2007. 
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Figure 3. Model for pathophysiology of RWA based on cat model. Each oval 
represents a distinct nuclei. Excitatory synapses are demonstrated with plus 
signs, inhibitory synapses with minus signs. The relative size of these symbols 
represents the magnitude of their effects. A cross out through an oval/nuclei 
represents an experimentally produced lesion. Relative tonic influences are 
represented by line thickness; thicker lines yield stronger influences while dotted 
lines represent the weakest due to damage. This representation shows the 
pathways by which lesions to certain brainstem nuclei, namely the Locus 
Coeruleus, may result in RWA. Figure annotated from B.F. Boeve Silber et al. 
2007. 
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  The other leading model for RWA and RBD pathology is the rat model. In 
the rat, the sublaterodorsal nucleus has been determined to be comparable to 
the subcoeruleus region in the cat and found to be a major REM sleep structure. 
In the rat model an area known as the REM-off region resides in the ventrolateral 
part of the periaqueductal grey matter (vlPAG) and lateral pontine tegmentum 
(LPT). This area is responsible for turning off the REM phase of sleep and 
perpetuating progression through the rest of the sleep cycle. Lesions in these 
areas will result in an increase in the amount of REM sleep experienced. These 
neurons are hyperpolarized by GABAergic (gamma-amniobutyric acid) 
projections from the forebrain and depolarized by projections from the Locus 
Coeruleus and pathways of the lateral hypothalamus (B F Boeve, Silber, et al., 
2007). 
 
  The REM-on region in the rat resides in the sublaterodorsal nucleus (SLD) 
and precoeruleus (PC) regions. These neurons have reciprocal interactions with 
the REM-off area and are mutually inhibitory.  The rat SLD projects to the 
medulla and spinal cord where it will inhibit anterior horn motor neurons, as seen 
in the cat model, and inhibit motor activity during REM sleep. Thereby it is 
proposed that lesions to the SLD leads to disinhibition of spinal motor neurons 
resulting in RWA (B F Boeve, Silber, et al., 2007). 
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Treatment Options 
 
  REM sleep behavior disorder treatment is largely symptomatic and most 
frequently recommended when there is a risk of injury or sleep disturbance to the 
patient or their bed partner. The two most frequently used treatments are 
clonazepam and exogenous melatonin. More often, clonazepam is used as a first 
line of treatment while melatonin is used as a second method (Trotti, 2010). 
 
  Clonazepam is a long acting benzodiazepine with a half-life of 30-40 hours 
and is rapidly absorbed after oral administration. Recommended doses range 
from .25mg- 2mg typically 30 minutes prior to bed. It has been noted that women 
may require a higher dose (Aurora et al., 2010). Clonazepam has been found to 
suppress atypical motor symptoms without restoring REM atonia (Trotti, 2010). 
The mechanism by which clonazepam works is through binding to 
benzodiazepine alpha receptors to promote GABAergic inhibition; this increased 
inhibition results in a reduced REM percentage while having little effect on 
muscle atonia (McCarter et al., 2013). In doing so, clonazepam reduces phasic 
muscle activity in REM sleep and improves the main features of RBD while still 
allowing RWA to be observed on PSG testing (Bradley F Boeve, 2010).  
 
  The use of clonazepam to treat RBD comes with side effects such as 
daytime sleepiness, muscle relaxation in the elderly, reduced sleep quality, 
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cognitive impairment or worsening of sleep apnea (Kunz & Mahlberg, 2010). 
Considering these side effects, clonazepam should be used with discretion in 
patients with obstructive sleep apnea, gait disorders or dementia. A recent study 
found 58% of 36 patients on clonazepam had moderate to severe side effects 
while taking this medication, leading to a significant rate of discontinuation. 
Failure to take clonazepam results in a rapid reoccurrence of RBD symptoms. 
However, discontinuation of clonazepam does not result in withdrawal symptoms 
and tolerance has not been observed. Despite the prevalence of side effects, 
larger studies have reported that more than 80% of patients improve while taking 
clonazepam (Aurora et al., 2010). Additionally, a study conducted in Hong Kong 
found the rate of sleep related injury as a result of RBD behavior decreased from 
80.8% pre-treatment to 5.6% after treatment with clonazepam (Wing et al., 
2008). 
 
  While melatonin is not as widely studied as clonazepam, it still offers a 
beneficial treatment for many patients (Aurora et al., 2010). Melatonin is believed 
to decrease the percent of REM sleep epochs without muscle atonia and 
decrease the stage shifts within REM sleep (Bradley F Boeve, 2010). A recent 
review of clinical practices investigated two retrospective case series which 
included a total of 38 RBD patients, 81.5% of which reported improvement on 
melatonin. The same clinical review found a significant decrease in the number 
of RWA epochs detected via PSG (Aurora et al., 2010), leading current research 
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to believe melatonin may help restore muscle atonia during REM sleep 
(McCarter et al., 2013). The mechanism by which melatonin is believed to 
decrease RBD symptoms is not well understood, but is currently believed to 
involve GABAergic inhibition and stabilization of circadian rhythm that often 
becomes misaligned in RBD. Melatonin may act to re-train the suprachiasmic 
nucleus to help restore circadian modulation (McCarter et al., 2013). 
 
  In healthy subjects, melatonin has been shown to increase the duration of 
the first REM episode of the night. In a small randomized study of 8 RBD patients 
by Kunz and Mahlberg, 87% of patients reported improvement in RBD symptoms 
and many reported decreased daytime sleepiness. These improvements were 
still felt after a washout period where the participants were asked to refrain from 
taking melatonin. Participants reported improvement lasting for 5 weeks after 
discontinuation; Indicating that melatonin has long lasting effects after 
administration. Additionally, Kunz and Mahlberg’s subjects reported a resolution 
of clinical RBD lasting up to 3 years after discontinuation of melatonin (Kunz & 
Mahlberg, 2010).   
   
Synucleinopathies 
 
  Between 38% and 65% of patients with idiopathic RBD (iRBD) followed 
longitudinally are found to develop an alpha synucleinopathy between 10 to 29 
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years after presentation of RBD (Aurora et al., 2010). This category of disorders 
is distinguished by the presence of Lewy bodies (LB) and Lewy neuritis (LN)- 
which are pathological aggregations of alpha synuclein (McKeith, 2005). 
Parkinson’s disease (PD), Dementia with Lewy bodies(DLB) and Multiple System 
Atrophy(MSA) all share the similarity of alpha synuclein positive intracellular 
inclusions, leading to these disorders to be jointly recognized as the 
synucleinopathies (B F Boeve, Silber, et al., 2007) 
 
  In cases of non-synucleinopathies, RBD occurs at the onset of, or after the 
presentation of the motor and cognitive features of the neurodegenerative 
disease. The information that RBD is more frequent in alpha-synucleinopathies 
indicates that despite Parkinson’s disease and neural degeneration, there are 
likely to be other abnormalities in the brain stem that result in the difference 
between syn and non-synucleinopathies (B F Boeve, Silber, et al., 2007). RBD 
appears to occur frequently in the synucleinopathies likely as a result of 
susceptibility in critical brain stem nuclei involved in RBD pathology being 
consistent with those involved in synucleinopathy pathology (Bradley F Boeve, 
2010).  
 
  Neuronal degeneration in PD and DLB is thought to initiate in the central 
nervous system and go on to impact peripheral neurons (Kaufmann, Nahm, 
Purohit, & Wolfe, 2004). The core features of DLB include fluctuation, visual 
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hallucinations and Parkinsonism. Progressive debilitating cognitive impairment is 
a requirement for the diagnosis of DLB (McKeith, 2005). In nearly every case of 
DLB there is pathology present in the brainstem, in the later stages the Lewy 
bodies are established in cortical areas of the brain (McKeith, 2005) (Dickson, 
Uchikado, Fujishiro, & Tsuboi, 2010). PD is believed to begin with alpha-
synuclein depositing in the medulla initially then progressing to rostral areas. This 
progression may explain RBD proceeding Parkinsonism and cognitive decline 
(Bradley F Boeve, 2010). 
 
 
              
 
 
 
 
  Braak Staging System of Lewy Body Pathology 
Table 1:  Summary of two staging systems for the distribution of 
Lewy Bodies in Parkinson’s Disease. This table shows the brain areas 
thought to be affected by PD and Lewy body pathology temporally. This 
representation clearly shows that the nuclei thought to be involved in RBD 
including the locus coeruleus and substantia nigra, are among those 
affected in the earliest stages of PD. Table taken from Dickson et al., 2010  
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  Recent studies have shown 70% of MSA patients, 40% of DLB patients, 
and 15-33% of PD patients present with comorbid RBD (Aurora et al., 2010). The 
Blonogna, Genova, Parma, and Pisa universities group for the study of RBD in 
PD used a questionnaire of 200 PD patients to reveal that 34% of their PD 
patients had suggestive histories of RBD (Scaglione et al., 2005). Most 
specialists in this discipline are beginning to view patients presenting RBD 
concurrently with cognitive impairment and/or parkinsonism as likely having an 
underlying synucleinopathy (Bradley F Boeve, 2010).  
 
  The data available on the topic of the RBD alpha-synucleinopathy 
relationship is very limited due to the lack of follow up over an extended period of 
time (Terzaghi et al., 2008). While literature is abundant on the subject, most of 
the studies and data are low level with small sample sizes (Aurora et al., 2010). . 
It is evident that RBD has a high prevalence in this population and may be able 
to serve as a pre-clinical risk factor and diagnostic measure in the detection of 
alpha-synucleinopathies. Further study of the correlation between RBD and 
synucleinopathies may allow for earlier and more accurate diagnosis, thereby 
possibly having implications in the treatment of these neurodegenerative 
disorders. 
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Specific Aims and Objectives 
 
  The objective of the present study is to investigate the correlation between 
REM sleep behavior disorder and the many aspects of alpha-synucleinopathies.  
Specifically: 
  1. To identify the presence of screening practices for RBD in movement  
  disorders patients.   
  2. To examine the prevalence of RBD in our population that was screened  
  for RBD and to stratify this by type of synucleinopathy. 
  3. To examine what methods they were treated with and if improvements  
  were noted among patients with at least one follow up visit. 
   4. To investigate the incidence of sleep related injuries to the patient and  
  their bed partner.  
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METHODS 
   
  This study was conducted by means of an internal review board approved 
retrospective chart review and analysis of 300 Boston Medical Center patients. 
These patient charts were obtained through the movement disorder outpatient 
clinic at Boston Medical Center and were all diagnosed with synucleinopathy 
from September 2006 through September 2011. 
 
  The charts were reviewed and relevant data was placed in a Microsoft 
Excel spread sheet. All data was obtained through reading clinical notes written 
by the treating physician. Data recorded included, but is not limited to, age, sex, 
synucleinopathy diagnosis, duration of synucleinopathy- for PD patients the 
severity of their disease was noted in the form of a Hoehn and Yahr (HY) scale 
scoring. The HY score was obtained by either their physician noting their score in 
the charts, or by us assessing the patient retrospectively from their most recent 
notes to determine what their HY score is likely to be given information noted in 
their chart. It was noted if the clinician screened for the presence of RBD via 
PSG or questions, RBD presence was then noted. Whether the patient was 
being treated for the RBD and what their treatment consisted of was recorded. 
Information regarding personal injury and injuries to sleeping partners as a result 
of RBD were noted. All medications for treatment of the synucleinopathy were 
noted as well as the time of each dosage. Other current medication information 
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was recorded. All medications were recorded from the most recent treatment 
plans noted in their charts. 
 
   There was no contact with the participants while obtaining data for this 
study. All patient identities were kept confidential via use of medical record 
numbers rather than personal identifiers. There were no exclusion criteria for our 
cohort. The participants were not compensated for their participation.  
 
  Statistical analysis included finding averages, standard deviations, and 
ranges of data collected. Correlational statistics included Wilcoxon sign tests, t-
tests, and regression analysis. These were computed by means of Microsoft 
excel, SPSS 21 and STATA.  
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RESULTS 
 
  Out of our sample size of 300, 79 (26.3%) were not screened for RBD by 
their physician. As a result, these participants were neither confirmed nor ruled 
out of RBD presence, their results were not used in any of the statistical analyses 
of significance for RBD correlations. As a result, the adjusted sample size of 
screened patients was 221. 
 
Synucleinopathy prevalence in the population: 
     73.3 %( 163) of our screened participants held a diagnosis of PD. 
Of these, 36.8 %( 60) had comorbid RBD. Seventy-nine out of the total 229 PD 
patients reviewed were not screened for RBD. A total of 8.1 % (18) of our 
screened participants had DLB, and 61% (11) of those were experiencing RBD. 
Three DLB participants were not screened for RBD, amounting to 21 DLB charts 
having been reviewed. 6 MSA charts were reviewed. 1.3 %( 3) of our screened 
participants held a diagnosis of MSA, 66% of those had RBD as well. 3 MSA 
participants were not screened for RBD by their providers.  51 charts with the 
diagnosis of Parkinsonism, a nonspecific synucleinopathy with Parkinson-like 
symptoms, were reviewed. 17.6 % (39) of our screened participants had 
Parkinsonism, of these 17.9% (7) also had RBD. Thirteen Parkinsonism 
participants were documented as being unscreened for RBD. 
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 Total Screened Screened 
with RBD 
Screened 
no RBD 
Unscreened 
PD 229 163 60 103 63 
MSA 6 3 2 1 3 
DLB 21 18 11 7 3 
Parkinsonism 51 39 7 32 13 
Dual 
Diagnosis 
7 - - - - 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Patients over each synucleinopathy and screening. This 
table demonstrates our participant numbers in regards to synucleinopathy 
diagnosis, RBD presence, and the presence of screening. 
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Figure 4.  Frequencies of each synucleinopathy in RBD screened 
participants.   Of our screened population, DLB consisted of 8.1 %, PD 
73.3%, MSA 1.3 %, Parkinsonism 17.6%, and 2.7 % had a dual diagnosis of 
more than one synucleinopathy.  
DLB
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Parkinsoism
Dual Diagnosis
 
PD 
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Figure 5. Comparison of screening and RBD diagnosis within 
each synucleinopathy. This figure graphically depicts the 
differences in population sizes, screening as well as RBD presence 
among the diagnoses. The bar furthest left in each section 
represents the total number of screened participants in each 
diagnosis. The middle bar of each represents the amount of those 
screened who were comorbid for RBD. The bar furthest right in each 
diagnoses shows the frequency of unscreened participants for that 
synucleinopathy.  
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 Descriptive statistics of the RBD-negative screened (n-RS), RBD-positive 
screened (p-RS), and non-screened groups:  
    The n-RS group consisted of 140 participants. 79 participants were 
un-screened and 79 participants were screened and found to have RBD.  The 
average age of the n-RS group was 71.6 years. The p-RS group had an average 
age of 70.9 years. The unscreened group had an average age of 72.4 years. The 
difference in ages between these three groups was not statistically significant by 
means of an independent samples T-test method of analysis.   
 
H&Y scores: 
  The average H&Y score, a scale of PD symptomology, of PD patients 
within the n-RS group was 2.79. The average H&Y score of PD patients within 
the p-RS group was 3.06. An average H&Y score of 2.81 was found for the non-
screened participants whom had PD. H&Y score was not found to be a significant 
predictor of RBD presence or the absence of screening when analyzed using a 
logistic regression method (P= .14).  
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 24% of the patients who were positive for RBD had charts that contained  
reports of partner complaints. 5% of RBD positive patients reported sleep related 
injuries as a result of their RBD. H&Y scores were not found to predict the 
likelihood of sustaining a sleep related injury in RBD-positive patients.  
 
 
 
Figure 6. Frequency of H&Y scores for screened non-RBD and RBD 
participants. This figure graphically demonstrates the distribution and 
frequency of H&Y scores for participants with RBD and those without RBD. 
The distribution is fairly similar between the two groups, with most participants 
having a H&Y score of 2 or 3. 
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 Synucleinopathy Duration: 
  The n-RS group of participants had average synucleinopathy duration of 
7.13 years. The p-RS group had an average synucleinopathy duration of 8.17 
years. The non-screened group was found to have an average synucleinopathy 
duration of 8.3 years. The duration of synucleinopathy was not found to 
significantly correlate to RBD presence or screening presence by means of a 
two-sample Wilcoxon rank-sum (Mann-Whitney) test (P=.49).  
 
RBD treatment methods: 
  Of the 79 RBD patients, 46.8% were treated for their RBD. Of those 
treated, 62% were treated with Clonazepam on a range of .25-1mg with an 
average dose of .5mg ±.16mg. A large proportion of treated patients (56.5%) 
reported improvements to their physicians which were documented in their 
charts. Melatonin was used to treat 37.8% of the RBD patients undergoing 
therapy, this method had a range of doses from 3-6mg with an average of 3.5mg 
±1.1mg and, 57.1% of these participants reported improvements. Other 
medications such as remeron were used to treat 2.7% of our participants, these 
reported 100% improvement. The difference in improvement seen between those 
on melatonin and those taking Clonazepam was not found to be significant.   
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Gender differences: 
  Of our total population, 57.3% of participants were male while 42.7% were 
female. In our study, 46.7% of our screened participants who were not exhibiting 
RBD were male. In contrast, 72.2% of our RBD population was male.  In our 
population, gender was found to have a statistically significant correlation with 
RBD presence by means of a logistic regression analysis (P<.000).  
 
Selective Serotonin Reuptake Inhibitor (SSSRI) Usage: 
 SSRI usage was reported in 24.2% of n-RS participants and in 32.9% of 
p-RS patients.  
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DISCUSSION 
 
   This study explored the relationship between RBD and alpha-
synucleinopathies in order to identify RBD groups most at risk for developing 
synucleinopathies and to determine what treatments may provide the best 
therapy for this population. 
 
  In recent studies, 38- 65% of iRBD patients were reported to later develop 
a synucleinopathy when followed prospectively. Related studies show 15-33% of 
PD patients were comorbid for RBD (Aurora et al., 2010). Our study found 36.8% 
of our PD population was comorbid for RBD. This figure is closely in line with 
those obtained by other researchers, although at the higher end of the spectrum. 
Research conducted by other groups found that 70% of MSA patients also 
suffered from RBD (Aurora et al., 2010). Our study found 66% to be comorbid for 
RBD. These are very similar figures, which is especially interesting given this 
study only had 3 MSA patients who were screened for RBD. While our 
retrospective analysis was unable to report on the temporal relationship of RBD 
with synucleinopathy, a recent study reported 87.8% of their MSA patients having 
RBD, of those 30% reported the RBD beginning before their MSA presented and 
63% reporting their RBD presenting after their MSA diagnosis (De Cock et al., 
2011). This information serves as perhaps a sign of differing brain pathology in 
MSA compared to that of the other synucleinopathies. However, even with such 
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a small population of MSA patients our figure for RBD prevalence in this 
population is very similar to that of other studies.  
 
  The Journal of Sleep Medicine has previously reported 40% of DLB 
patients having been documented as suffering from RBD (Aurora et al., 2010). In 
our DLB population, 61% were screened and found to be exhibiting RBD. This is 
a somewhat larger number than previously reported studies. It is possible that 
the providers in the movement disorders clinic from which these charts were 
pulled are more aware of the RBD correlation in DLB and may be more diligent in 
exploring its presence in their patients than physicians in other clinics.  
 
  Despite some studies indicating that PD patients with clinical RBD have 
more severe Parkinsonism symptoms than those without RBD; In our study, 
Hoehn and Yahr scores were not found to correlate with RBD presence (Nomura, 
Inoue, Kagimura, & Nakashima, 2012). A higher Hoehn and Yahr score, which 
describes a more progressed PD symptomology, was not found to be indicative 
of an increased likelihood of being comorbid of RBD. This may be because the 
H&Y score is a scale only of symptom presentation- this score changes with 
medication and treatment. Patients may initially present with a H&Y score of 4, 
but after appropriate treatment their PD may progress back to a score of 2, 
indicating a less symptomatic stage than their initial presentation. As a result, 
scores fluctuate with medication compliance and treatment. H&Y scores used for 
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this study were noted as being the most recent in the participant’s chart. 
Additionally, the H&Y scale is not indicative of brain degeneration and the Braak 
and Braak stages of PD pathology (Burke, Dauer, & Vonsattel, 2008). However, 
since RBD often presents decades before the clinical presentation of 
synucleinopathies,  it is likely that the Braak and Braak stage would be at most a 
1 at the time of first RBD presentation given the time and lack of synucleinopathy 
symptomology (Claassen et al., 2010). 
 
  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) is a 
drug that destroys specifically targeted dopaminergic neurons of the substantia 
nigra. This drug has been found to experimentally mimic the degeneration 
pattern of PD. MPTP administration in marmosets have produced in RBD- (as 
well as PD), and have allowed for dissection and analysis of brain degeneration 
in primates. This model hypothesizes that the degeneration process of PD is 
initiated in the medulla, then progress to the pons where it goes on to target the 
mid-brain. Thereby, the presence of RBD may indicate early involvement of non-
dopaminergic medullary or pontine REM related structures. These REM related 
structures are closely connected to the substantia nigra and its pathways. As a 
result the REM related structures are likely affected by the dopamine imbalance 
caused by the early administration of MPTP, or early progression of PD (Verhave 
et al., 2011). Significant damage to the substantia nigra is not noted till Braak and 
Braak stage 3 (Dickson et al., 2010). Therefore,  small early changes in 
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dopaminergic neurons may lead to effects in REM sleep many years ahead of 
PD presentation.  
 
  In our patient population, 36 % of our screened participants were found to 
have RBD as well as a synucleinopathy. Of those, 46.8% were treated for their 
RBD. 62% were treated on clonazepam and 37.8% were treated with melatonin. 
Clonazepam is commonly accepted as the most widely used form of treatment 
for RBD, so this treatment disparity is not surprising. 56.5% of our clonazepam 
patients reported improvements, while 57.1% of our melatonin patients reported 
improvement. In similar studies 80% of patients reported improvements on 
clonazepam and 81% reported improvements on melatonin (Aurora et al., 2010). 
It is interesting to note that in both, our study and that done by Aurora et al., the 
difference in improvement between melatonin and clonazepam patients is 
minimal. Both appear to be equally effective.  It is possible our improvement 
results are lower due to reasons including physicians not recording this 
improvement in the patients’ charts, increasing cognitive decline being an issue 
in judging the effectiveness via the patients self-report, or it may be due to a lack 
of patient follow-up.  
 
  Interestingly, only 46.8% of our RBD patient population was treated for 
their RBD.  This information implies that it is often acceptable to not treat this 
condition. By the time they came into the movement disorders clinic from which 
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these patients’ charts’ were pulled. Many patients were already sleeping 
separately from their partners. Additionally, unlike other studies, our population 
all had movement disorders; perhaps this characteristic impaired their ability to 
fully exhibit RBD flailing movements and thereby posed less of a risk to bed 
partners. Our RBD population reported having sustained sleep related injuries 
(5%), and 24% reported partner complaints. A study conducted on RBD in Hong 
Kong found 80% of RBD patients had injured themselves during an RBD episode 
(Wing et al., 2008). Our patient population had substantially fewer reports of 
sleep related injuries, which may be a result of their movement disorder impairing 
their movements during RBD and thereby making treatment of the RBD less 
imperative.  
 
  The side effects of medication may also have contributed to fewer patients 
being treated for RBD. Clonazepam is known to have side effects including gait 
instability and clouded cognition (Aurora et al., 2010). These side effects may 
prove to be too great of a risk in a patient population that is already prone to gait 
instability and suffers from cognitive decline as a result of their synucleinopathy. 
The RBD episodes in our population may also be deemed too infrequent to 
warrant treatment. It is also possible that RBD may spontaneously resolve in our 
population, thereby lessening the need for treatment.  
 
  SSRI’s are currently being evaluated for their potential to unmask or 
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potentially result in RBD symptomology. This association is strong; however it 
appears more often in early-onset cases. It has been long reported that SSRI 
usage in narcoleptic patients induced excessive motor activities in the REM sleep 
stage. Studies have explored this correlation regarding SSRI’s between early and 
late onset RBD. In early onset cases, these studies found 80% and 57% of RBD 
patients to be on SSRIs. In late onset cases 46% and 38% of RBD participants 
were found to be taking SSRIs. Among all individuals in the general population 
taking SSRIs, 5% report RBD behaviors. Studies show SSRI usage among 
parasomnia sufferers to be higher than that found in the general population (Ju, 
2013). In our study, 24.2% of our screened population who was not found to be 
suffering from RBD was on an SSRI. Meanwhile, 32.9% of our RBD group was 
found to be on SSRIs. Our rate of SSRI usage in RBD patients is somewhat less 
than reported by other studies. This may be a result of prescribing practices of 
the physicians in the movement disorders clinic from which these charts were 
pulled. It also may be a result of side effects in conjunction with their movement 
disorders making the use of SSRIs less desirable. It is also possible that our 
participants are so far progressed in their disease that SSRIs would no longer 
have an effect on RBD presentation, and that the SSRI correlation is largely a 
phenomena of early onset RBD and cases long before the presentation of 
synucleinopathy.  
 
  In RBD populations there is a commonly reported gender disparity. In late 
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onset IRBD (idiopathic REM sleep behavior disorder) is found to be much more 
prevalent in men than it is in women. In early onset iRBD, men and women are 
equally likely to present (McCarter et al., 2013). 87% of RBD sufferers were 
reported to be male in a recent study of 93 patients in a sleep clinic (Olson et al., 
2000). In our population, 46.7% of our screened participants who were not 
exhibiting RBD were male. In contrast, 72.2% of our RBD population was male. 
While this number is still large, it is noticeably smaller than other reports on the 
gender disparity. This may be a function of the gender bias being a sign of 
increased sensitivity in males to RBD presentation that may decrease with 
disease progression. Most studies on RBD are conducted prospectively from 
sleep labs. Our study was completed retrospectively from a movement disorders 
clinic; this may explain why our gender imbalance was less than that of other 
studies. If males are more likely to display RBD earlier it would be logical for 
them to be more prevalent in studies that are designed prospectively beginning in 
a sleep clinic. Additionally, females may not report their RBD are frequently as 
men. It is possible that the excessive motor actions of females may be of less 
disturbance than that typically exhibited by men, and are thereby brought up to 
medical providers less frequently.  
 
   Our RBD patients had an average age of 70.9 years, the average age of 
RBD diagnosis is in the 60’s or 70’s with a frequent 4-5 year period until the 
patient is formally diagnosed with the condition (Trotti, 2010). This study was 
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unable to make note of the age of RBD onset, due to the nature of retrospective 
analysis and missing data. Our RBD patients presented with an average 
synucleinopathy duration of 8.17 years. It is possible to imagine many of our 
participants might have had their RBD begin in their 50’s given the approximately 
5 years it takes on average to recognize RBD, the duration of the 
synucleinopathy, and the often long time between RBD presentation and 
synucleinopathy diagnosis. RBD cases presenting before the age of 50 are 
considered to be early onset, and tend to have a smaller gender disparity (Ju, 
2013). 
 
  Few studies have been conducted regarding RBD screening practices, 
particularly those used in the synucleinopathy population. 25% of our participants 
had no documentation of screening in their charts. This may be the result of 
either non-report by the physician, or a lack of screening.  
 
 Limitations: 
 
  This study was a retrospective analysis via chart reviews. As a result, we 
were only able to assess data provided by healthcare providers by means of 
patient charts. Many points of data were therefore missing, such as time of RBD 
onset, melatonin doses, and screening practices. By doing a retrospective review 
it is difficult to conclude temporal relationships between factors.  
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  Our study was also subject to a selection and regional bias. While this was 
a limitation, it was also a unique feature of our study. Most studies on RBD are 
conducted on patients referred to a sleep center. In our study, the participants 
were taken from a movement disorders clinic. As a result, our synucleinopathy 
patients were likely further along in their disease than those normally studied by 
prospective means. Additionally, 100% of our participants were already 
diagnosed with a synucleinopathy- a correlation many studies explore 
prospectively.  
  
Future Directions: 
  
  Future studies should be done to further explore the effectiveness of 
melatonin and clonazepam in the synucleinopathy population; given the 
uniqueness of their degeneration other therapeutics may prove to be more 
beneficial. Additionally, more research should be done on whether it is 
advantageous to treat RBD in this population or if it is indeed acceptable to 
pursue non-treatment of RBD in synucleinopathy populations. 
 
  The gender bias in synucleinopathy patients presenting with RBD is also 
an area warranting more research. More studies should be done to explore if this 
disparity diminishes with the progression of the synucleinopathies. By pursuing a 
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better understanding of the gender bias it may be possible to better identify those 
at risk for developing a synucleinopathy and perhaps aid in finding better early 
detection methods for females. 
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